Maxime Verhoeven

117 Effectiveness and safety of treat-to-target strategies over 5 years 10. Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 , 343–355 (2016). 11. Quartagno, A. M., Carpenter, J. & Quartagno, M. M. Package ‘ jomo ’ . (2018). 12. Marshall, A., Altman, D. G., Holder, R. L. & Royston, P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med. Res. Methodol. 9 , 57 (2009). 13. Smolen, J. S. & Aletaha, D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 63 , 43–52 (2011). 14. Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 68 , 1580–1584 (2009). 15. Kremer, J. M. et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin. Exp. Rheumatol. 34 , 625–633 (2016). 16. Jones, G. et al. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or free of methotrexate for 6 months: the AMBITION study. J. Rheumatol. 44 , 142-146 (2016). 6